To include your compound in the COVID-19 Resource Center, submit it here.

Merck KGaA to drop further IMO-2055 development

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) said Merck KGaA (Xetra:MRK) will not conduct further development of IMO-2055 to treat cancer after an increased incidence

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE